{"id":11,"date":"2022-09-09T21:14:15","date_gmt":"2022-09-09T21:14:15","guid":{"rendered":"https:\/\/oncolodyne.live-website.com\/?page_id=11"},"modified":"2025-02-27T20:42:11","modified_gmt":"2025-02-27T20:42:11","slug":"who-we-are","status":"publish","type":"page","link":"https:\/\/oncolodyne.com\/?page_id=11","title":{"rendered":"Who we are"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">Aamir Ahmed &#8211; Founder and CEO<\/h2>\n\n<figure class=\"wp-block-image alignleft  size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" class=\"\" src=\"https:\/\/oncolodyne.com\/wp-content\/uploads\/2025\/02\/AA_IMG_4601-scaled-1.jpeg\" width=\"202\" height=\"271\" \/><\/figure>\n<p>Aamir obtained his PhD from the University of Dundee where he also served as an Honorary Lecturer and Group Leader.\u00a0 \nHe then joined Yale University as research faculty to work on ion channels. Aamir was awarded a Wellcome Trust Fellowship at the Department of Physiology, University College London, where he established his research group. \nThis was followed by his appointment as the Head of Stem Cell Group at the Prostate Cancer Research Centre, at the University College London and later at the Centre for Stem Cells and Regenerative Medicine, King\u2019s College London. Aamir discovered novel roles and mechanisms of cell signaling pathways, particularly the Wnt pathway which is critical in the process of carcinogenesis. Aamir founded Oncolodyne to translate this knowledge into therapies for cancer. <Br><Br><Br><Br>. <\/p>\n<p><!-- \/wp:post-content --><\/p>\n<p><!-- wp:heading --><\/p>\n<h2 class=\"wp-block-heading\">Mike Millar Chief Technical Officer<\/h2>\n<!-- \/wp:heading -->\n<figure class=\"wp-block-image alignleft size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" class=\"\" src=\"https:\/\/oncolodyne.com\/wp-content\/uploads\/2023\/04\/profile-1-scaled-e1693439452618.jpg\" width=\"202\" height=\"271\" \/><\/figure>\n<p>Mike is a former HPC registered Biomedical Scientist, former MHRA GLP accredited laboratory manager, and is currently a GCLP test facility manager. The founder of Histoplex, the UK&#8217;s first RNAscope service provider which is now part of Aquila Biomedicals specialist multiplex histology lab. \nA key strength of Mike&#8217;s laboratory is developing robust, reproducible immunochemical assays using multiplex labelling in human tissue using both antibodies and RNA probes. \nMike&#8217;s research spans several decades with 90 peer reviewed publications and over 7000 citations for tissue based research in both commercial and academic in the areas covering reproduction to cancer. Mike has also developed various innovative immunohistochemical protocols for industry \n<Br><Br><Br><Br>.<\/p>\n<p><!-- \/wp:heading --><\/p>\n<p><!-- wp:heading --><\/p>\n<h2 class=\"wp-block-heading\">Norman Williams &#8211; Clinical Trials Director<\/h2>\n<p><!-- \/wp:heading --><\/p>\n<figure class=\"wp-block-image alignleft size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" class=\"\" src=\"https:\/\/oncolodyne.com\/wp-content\/uploads\/2025\/02\/Norman.jpeg\" width=\"202\" height=\"271\" \/><\/figure>\n<p>Norman obtained his PhD at the Royal Postgraduate Medical School in London where he ran his first clinical trial. He then moved to the Royal Papworth Hospital and the University of Cambridge where he led a team of researchers investigating factors associated with cardiovascular disease. Next, Norman moved to University College London where he has been integral in establishing an academic clinical trials unit. Norman has over 30 years of experience in designing, conducting and managing national and international single and multi-centre clinical trials and running these efficiently and on time. Results from many of these clinical trials have changed clinical practice. A new focus of his research is designing and conducting clinical trials for repurposed drugs<Br><Br><Br><Br>.<\/p>\n<p><!-- \/wp:heading --><\/p>\n<p><!-- wp:heading --><\/p>\n<h2 class=\"wp-block-heading\">Chris Thrasivoulou &#8211; Company Secretary<\/h2>\n<p><!-- \/wp:heading --><\/p>\n<figure class=\"wp-block-image alignleft size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" class=\"\" src=\"https:\/\/oncolodyne.com\/wp-content\/uploads\/2023\/07\/CT-mono-scaled.jpg\" width=\"202\" height=\"271\" \/><\/figure>\n<p>Chris \u00a0obtained his PhD from University College London\u00a0 and is currently Director of UCL\u2019s Division of Biosciences Imaging\u00a0\u00a0Facility. This large state-of-the -art imaging unit serves over 900 researchers from a very diverse range of science disciplines across UCL. Chris\u2019s research interest began in the field of neuroanatomy and the effects of aging and caloric restriction in the central and peripheral nervous sstem at the Royal Free Hospital School of Medicine. Chris moved to UCL in 2002 and leads the Centre for Cell and Molecular Dynamics Imaging unit and also heads the UCL\/Zeiss Multiscale Imaging Centre, since its inception in 2019. He has secured multi-million pound grant funding with colleagues at UCL for the Multiscale Imaging Centre Chris \u00a0obtained his PhD from University College London\u00a0 and is currently Director of UCL\u2019s Division of Biosciences Imaging\u00a0\u00a0Facility. This large state-of-the -art imaging unit serves over 900 researchers from a very diverse range of science disciplines across UCL. Chris\u2019s research interest began in the field of neuroanatomy and the effects of aging and caloric restriction in the central and peripheral nervous sstem at the Royal Free Hospital School of Medicine.<br><Br><Br><Br><\/p>\n<p><!-- wp:heading --><\/p>\n<p><!-- wp:heading --><\/p>\n<h2 class=\"wp-block-heading\">Ibrahim Hashmi &#8211; Chief Operating Officer<\/h2>\n<p><!-- \/wp:heading --><\/p>\n<figure class=\"wp-block-image alignleft size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" class=\"\" src=\"https:\/\/oncolodyne.com\/wp-content\/uploads\/2025\/02\/Dr-Ibrahim-Hashmi.jpeg\" width=\"202\" height=\"271\" \/><\/figure>\n<p>Ibrahim obtained his MBBS from the Sind Medical College Karachi and practiced medicine before moving into industry. Because of his background in medicine and industry he has experience in wide ranging spheres including medical, commercial, marketing, logistics, supply chain, finance, compliance and regulatory affairs. He has over 25 years of commercial management experience as a leader of multifunctional teams. Until recently, Ibrahim worked with a large multi-national where he led multi-cultural stakeholders\u00a0 across Asia-Pacific, Middle East and Central Asia working in synergy with European and US segments of the organization.\u00a0 Through his career, Ibrahim has proved himself as a result-oriented executive with unique medical and business acumen with a strong strategic focus<br><Br><Br>.<\/p>\n<h2 class=\"wp-block-heading\">Recent publications from the Oncolodyne team<\/h2>\n<p style=\"text-align: left;\">Xie, B., Zuhair, H., Henrique, R., Millar, M., Robson, T., Thrasivoulou, C., Dickens, K., Pendjiky, J., Muneer, A., Patel, H., and Ahmed, A. (2023) Opposite changes in the expression of clathrin and caveolin-1 in normal and cancerous human prostate tissue: putative clathrin-mediated recycling of EGFR. <em>Histochem Cell Biol<\/em> DOI: <a href=\"https:\/\/doi.org\/10.1007\/s00418-023-02183-8\">10.1007\/s00418-023-02183-8 <\/a><\/p>\n<p>Arthurs C, Ahmed A. QuArray: an application for tissue array whole slide image export and signal analysis. Bioinformatics. 2021.<\/p>\n<p>Ashmore J, Olsen H, Sorensen N, Thrasivoulou C, Ahmed A. Wnts control membrane potential in mammalian cancer cells. J Physiol. 2019;597(24):5899-914.<\/p>\n<p>Reyes-Corral M, Sorensen NM, Thrasivoulou C, Dasgupta P, Ashmore JF, Ahmed A. Differential Free Intracellular Calcium Release by Class II Antiarrhythmics in Cancer Cell Lines. J Pharmacol Exp Ther. 2019. doi: 10.1124\/jpet.118.254375<\/p>\n<p>Petrou T, Olsen HL, Thrasivoulou C, Masters JR, Ashmore JF, Ahmed A. Intracellular Calcium Mobilization in Response to Ion Channel Regulators via a Calcium-Induced Calcium Release Mechanism. J Pharmacol Exp Ther. 2017;360(2):378-87.<\/p>\n<p>Cosia, C, Millar, M, Beltran, M, Sherry, L, Gatti-McArthur, S. (2021) <em>Quantitative analysis of RNAscope staining for\u00a0c-fos\u00a0expression in mouse brain tissue as a measure of Neuronal Activation<\/em>,\u00a0<a href=\"https:\/\/www.sciencedirect.com\/science\/journal\/22150161\">MethodsX<\/a>\u00a0<a href=\"https:\/\/www.sciencedirect.com\/science\/journal\/22150161\/8\/supp\/C\">Volume 8<\/a>,\u00a02021, 101348<\/p>\n<p>Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, Soong DYH, Cotechini T, Anur P, Lin EY, Fidanza A, Lopez-Yrigoyen M, Millar MR, Urman A, Ai Z, Spellman PT, Hwang ES, Dixon JM, Wiechmann L, Coussens LM, Smith HO, Pollard JW. Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets. Cancer Cell 2019; 35: 588-602 e1<\/p>\n<p>Millar, M (2020<em>) Mixed Multiplex Staining: Automated RNAscope\u2122 and OPAL\u2122 for Multiple TargetsMethods in molecular biology<\/em>\u00a0(Clifton, N.J.)\u00a02148:277-298 DOI:\u00a0<a href=\"http:\/\/dx.doi.org\/10.1007\/978-1-0716-0623-0_18\" target=\"_blank\" rel=\"noreferrer noopener\">10.1007\/978-1-0716-0623-0_18<\/a> In book: In Situ Hybridization Protocols<\/p>\n<p>Catto JWF, Khetrapal P, Ricciardi F, Ambler G, Williams NR, Al-Hammouri T, Khan MS, Thurairaja R, Nair R, Feber A, Dixon S, Nathan S, Briggs T, Sridhar A, Ahmad I, Bhatt J, Charlesworth P, Blick C, Cumberbatch MG, Hussain SA, Kotwal S, Koupparis A, McGrath J, Noon AP, Rowe E, Vasdev N, Hanchanale V, Hagan D, Brew-Graves C, Kelly JD. Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer: A Randomized Clinical Trial. JAMA. 2022 Jun 7;327(21):2092-2103. doi: 10.1001\/jama.2022.7393. PubMed PMID: 35569079; PubMed Central PMCID: PMC9109000.<\/p>\n<p>Shah TT, Kanthabalan A, Otieno M, Pavlou M, Omar R, Adeleke S, Giganti F, Brew-Graves C, Williams NR, Grierson J, Miah H, Emara A, Haroon A, Latifoltojar A, Sidhu H, Clemente J, Freeman A, Orczyk C, Nikapota A, Dudderidge T, Hindley RG, Virdi J, Arya M, Payne H, Mitra A, Bomanji J, Winkler M, Horan G, Moore CM, Emberton M, Punwani S, Ahmed HU. Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After Radiotherapy. Eur Urol. 2022 Jun;81(6):598-605. doi: 10.1016\/j.eururo.2022.02.022. Epub 2022 Mar 31. PubMed PMID: 35370021; PubMed Central PMCID: PMC9156577.<\/p>\n<p>Orczyk C, Barratt D, Brew-Graves C, Peng Hu Y, Freeman A, McCartan N, Potyka I, Ramachandran N, Rodell R, Williams NR, Emberton M, Ahmed HU. Prostate Radiofrequency Focal Ablation (ProRAFT) Trial: A Prospective Development Study Evaluating a Bipolar Radiofrequency Device to Treat Prostate Cancer. J Urol. 2021 Apr;205(4):1090-1099. doi: 10.1097\/JU.0000000000001567. Epub 2020 Dec 14. PubMed PMID: 33315505.<\/p>\n<p><!-- \/wp:paragraph --><\/p>\n<p><!-- wp:paragraph --><\/p>\n<p>Milosevic M, Edwards J, Tsang D, Dunning J, Shackcloth M, Batchelor T, Coonar A, Hasan J, Davidson B, Marchbank A, Grumett S, Williams NR, Macbeth F, Farewell V, Treasure T. Pulmonary Metastasectomy in Colorectal Cancer: updated analysis of 93 randomized patients &#8211; control survival is much better than previously assumed. Colorectal Dis. 2020 Oct;22(10):1314-1324. doi: 10.1111\/codi.15113. Epub 2020 Jun 14. PubMed PMID: 32388895; PubMed Central PMCID: PMC7611567.<\/p>\n<p><!-- \/wp:paragraph --><\/p>\n<p><!-- wp:paragraph --><\/p>\n<p><!-- \/wp:paragraph --><\/p>\n<p><!-- wp:paragraph --><\/p>\n<p>Hamid S, Donaldson IA, Hu Y, Rodell R, Villarini B, Bonmati E, Tranter P, Punwani S, Sidhu HS, Willis S, van der Meulen J, Hawkes D, McCartan N, Potyka I, Williams NR, Brew-Graves C, Freeman A, Moore CM, Barratt D, Emberton M, Ahmed HU. The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance Imaging\/Ultrasound Image-fusion Targeted Biopsies for Prostate Cancer Risk Stratification. Eur Urol. 2019 May;75(5):733-740. doi: 10.1016\/j.eururo.2018.08.007. Epub 2018 Dec 6. PubMed PMID: 30527787; PubMed Central PMCID: PMC6469539.<\/p>\n<p><!-- \/wp:paragraph --><\/p>\n<p><!-- wp:paragraph --><\/p>\n<p><!-- \/wp:heading --><\/p>\n<p><!-- wp:paragraph --><\/p>\n<p><!-- \/wp:paragraph --><\/p>","protected":false},"excerpt":{"rendered":"<p>Aamir Ahmed &#8211; Founder and CEO Aamir obtained his PhD from the University of Dundee where he also served as an Honorary Lecturer and Group Leader.\u00a0 He then joined Yale [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-11","page","type-page","status-publish","czr-hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Who we are - Oncolodyne<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/oncolodyne.com\/?page_id=11\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Who we are - Oncolodyne\" \/>\n<meta property=\"og:description\" content=\"Aamir Ahmed &#8211; Founder and CEO Aamir obtained his PhD from the University of Dundee where he also served as an Honorary Lecturer and Group Leader.\u00a0 He then joined Yale [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/oncolodyne.com\/?page_id=11\" \/>\n<meta property=\"og:site_name\" content=\"Oncolodyne\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-27T20:42:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/oncolodyne.com\/wp-content\/uploads\/2025\/02\/AA_IMG_4601-scaled-1.jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/oncolodyne.com\/?page_id=11\",\"url\":\"https:\/\/oncolodyne.com\/?page_id=11\",\"name\":\"Who we are - Oncolodyne\",\"isPartOf\":{\"@id\":\"https:\/\/oncolodyne.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/oncolodyne.com\/?page_id=11#primaryimage\"},\"image\":{\"@id\":\"https:\/\/oncolodyne.com\/?page_id=11#primaryimage\"},\"thumbnailUrl\":\"https:\/\/oncolodyne.com\/wp-content\/uploads\/2025\/02\/AA_IMG_4601-scaled-1.jpeg\",\"datePublished\":\"2022-09-09T21:14:15+00:00\",\"dateModified\":\"2025-02-27T20:42:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/oncolodyne.com\/?page_id=11#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/oncolodyne.com\/?page_id=11\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/oncolodyne.com\/?page_id=11#primaryimage\",\"url\":\"https:\/\/oncolodyne.com\/wp-content\/uploads\/2025\/02\/AA_IMG_4601-scaled-1.jpeg\",\"contentUrl\":\"https:\/\/oncolodyne.com\/wp-content\/uploads\/2025\/02\/AA_IMG_4601-scaled-1.jpeg\",\"width\":1911,\"height\":2560},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/oncolodyne.com\/?page_id=11#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/oncolodyne.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Who we are\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/oncolodyne.com\/#website\",\"url\":\"https:\/\/oncolodyne.com\/\",\"name\":\"Oncolodyne\",\"description\":\"An oncology drug discovery and reprofiling company\",\"publisher\":{\"@id\":\"https:\/\/oncolodyne.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/oncolodyne.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/oncolodyne.com\/#organization\",\"name\":\"Oncolodyne\",\"url\":\"https:\/\/oncolodyne.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/oncolodyne.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/oncolodyne.com\/wp-content\/uploads\/2023\/01\/cropped-Oncolodyne-Blue-Logo.png\",\"contentUrl\":\"https:\/\/oncolodyne.com\/wp-content\/uploads\/2023\/01\/cropped-Oncolodyne-Blue-Logo.png\",\"width\":1317,\"height\":526,\"caption\":\"Oncolodyne\"},\"image\":{\"@id\":\"https:\/\/oncolodyne.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Who we are - Oncolodyne","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/oncolodyne.com\/?page_id=11","og_locale":"en_GB","og_type":"article","og_title":"Who we are - Oncolodyne","og_description":"Aamir Ahmed &#8211; Founder and CEO Aamir obtained his PhD from the University of Dundee where he also served as an Honorary Lecturer and Group Leader.\u00a0 He then joined Yale [&hellip;]","og_url":"https:\/\/oncolodyne.com\/?page_id=11","og_site_name":"Oncolodyne","article_modified_time":"2025-02-27T20:42:11+00:00","og_image":[{"url":"https:\/\/oncolodyne.com\/wp-content\/uploads\/2025\/02\/AA_IMG_4601-scaled-1.jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/oncolodyne.com\/?page_id=11","url":"https:\/\/oncolodyne.com\/?page_id=11","name":"Who we are - Oncolodyne","isPartOf":{"@id":"https:\/\/oncolodyne.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/oncolodyne.com\/?page_id=11#primaryimage"},"image":{"@id":"https:\/\/oncolodyne.com\/?page_id=11#primaryimage"},"thumbnailUrl":"https:\/\/oncolodyne.com\/wp-content\/uploads\/2025\/02\/AA_IMG_4601-scaled-1.jpeg","datePublished":"2022-09-09T21:14:15+00:00","dateModified":"2025-02-27T20:42:11+00:00","breadcrumb":{"@id":"https:\/\/oncolodyne.com\/?page_id=11#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/oncolodyne.com\/?page_id=11"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/oncolodyne.com\/?page_id=11#primaryimage","url":"https:\/\/oncolodyne.com\/wp-content\/uploads\/2025\/02\/AA_IMG_4601-scaled-1.jpeg","contentUrl":"https:\/\/oncolodyne.com\/wp-content\/uploads\/2025\/02\/AA_IMG_4601-scaled-1.jpeg","width":1911,"height":2560},{"@type":"BreadcrumbList","@id":"https:\/\/oncolodyne.com\/?page_id=11#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/oncolodyne.com\/"},{"@type":"ListItem","position":2,"name":"Who we are"}]},{"@type":"WebSite","@id":"https:\/\/oncolodyne.com\/#website","url":"https:\/\/oncolodyne.com\/","name":"Oncolodyne","description":"An oncology drug discovery and reprofiling company","publisher":{"@id":"https:\/\/oncolodyne.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/oncolodyne.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/oncolodyne.com\/#organization","name":"Oncolodyne","url":"https:\/\/oncolodyne.com\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/oncolodyne.com\/#\/schema\/logo\/image\/","url":"https:\/\/oncolodyne.com\/wp-content\/uploads\/2023\/01\/cropped-Oncolodyne-Blue-Logo.png","contentUrl":"https:\/\/oncolodyne.com\/wp-content\/uploads\/2023\/01\/cropped-Oncolodyne-Blue-Logo.png","width":1317,"height":526,"caption":"Oncolodyne"},"image":{"@id":"https:\/\/oncolodyne.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/oncolodyne.com\/index.php?rest_route=\/wp\/v2\/pages\/11","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncolodyne.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/oncolodyne.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/oncolodyne.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/oncolodyne.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11"}],"version-history":[{"count":146,"href":"https:\/\/oncolodyne.com\/index.php?rest_route=\/wp\/v2\/pages\/11\/revisions"}],"predecessor-version":[{"id":479,"href":"https:\/\/oncolodyne.com\/index.php?rest_route=\/wp\/v2\/pages\/11\/revisions\/479"}],"wp:attachment":[{"href":"https:\/\/oncolodyne.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}